

Supplementary Information

Table S1. Identification of MUC5B and MUC5AC in submucosal gland secretions.

The major high molecular weight glycoprotein in submucosal gland secretions migrating with a molecular mass of ~4 MDa by 1D SDS-AgPAGE was excised and digested with trypsin, and the resulting peptides were analysed by MALDI-TOF-MS. PMF searching identified the presence of (A) MUC5B and (B) MUC5AC. Details of the proteins identified, masses of the tryptic peptides detected, error to the theoretical peptide masses, the position of the peptides within each protein, and the peptide sequences are shown for CF subject 1. This data is representative of all subjects.

A		Protein	SwissProt Accession	MW (Da)	pI	Unique Peptide Hits	% Coverage
		Mucin 5B	Q9HC84	590122	6.24	42	10.56
m/z	Error (ppm)	Peptide Position			Alkylated Cysteines	Peptide Sequence	
605.3	34.2	5364-5368				FPGER	
722.4	33.3	1009-1014				TSVFIR	
879.4	-56.5	5283-5289			1	GVCSDWIR	
893.4	34.5	155-161				EELPYSR	
906.4	-39.5	1588-1593			1	MCYNYR	
931.5	-69.8	321-327			2	CPELCPR	
960.6	-62.2	678-685				GVQLSDWR	
973.6	-46.6	5190-5197				TWLVPSDR	
1036.6	-38.3	2362-2371, 2891-2900, 3589-3598				AQAQPGVPLR	
1077.5	-47.6	1070-1078			1	DPCTANPFR*	
1107.6	-24.0	626-635				LTDPNSAFSR	
1132.5	-33.6	2398-2405, 2927-2934, 3625-3632, 4154-4161			1	MCFNYEIR	
1140.7	4.6	121-131				GLVGSRPVVTR	
1258.7	44.4	226-236				LTPQLFGNLQK	
1325.7	-53.6	109-119				AAYEDFNQLR	
1364.7	-52.8	1867-1876			1	FNMCFNYNVR	
1468.8	-40.5	456-468			1	CADSSFTVLAELR	
1498.8	-36.9	1567-1578			2	VHCDVHFGLVCR	
1508.7	38.8	1044-1057				SVVGDALEFGNSWK	
1539.8	2.6	455-468				KCADSSFTVLAELR	
1539.8	2.6	456-469				CADSSFTVLAELRK*	
1617.8	-41.4	1085-1098			2	QCSILHGPTFAACR	
1630.8	-44.1	2346-2361, 2875-2890, 3573-3588, 4102-4117			1	AAGGAVCEQPLGLECR	
1679.9	-54.5	1369-1382			2	GYQVCPVLADIECR	
1687.8	-29.9	2346-2361, 2875-2890, 3573-3588, 4102-4117			2	AAGGAVCEQPLGLECR*	
1724.9	-40.7	938-954				IVTENIPCGTTGTTCSK*	
1747.8	-37.6	294-307			3	CPTCPATFVEYSR	
1848.0	-43.5	5305-5320			2	VYKPCGPIQATCNSR	
1938.0	-41.2	5265-5280			2	LEVPCQSLAAYALCR	
1981.0	-34.2	2372-2388, 2901-2917, 3599-3615			2	ELGQVVECSLDFGLVCR	
2027.9	12.6	1766-1784				TETTMSPLTNTTTSQGTTR	
2113.0	-40.1	659-677			3	SEDCLCAALSSVYHACAAK	
2113.0	-7.3	1182-1200			2	NPSGHCLVDLPGLEGCYPK	
2122.9	-21.4	4906-4922			3	AGCHFVAVCNQHCDIDR	
2151.0	27.4	938-957			2	IVTENIPCGTTGTTCSKAIK	
2257.9	-15.6	5632-5649				YSAEAAQAMHQCTCCQER	
2257.9	39.1	1021-1041			3	GRVCGLCGNFDDNAINDFATR	
2262.1	-35.1	1405-1424				GLMCANSQSQSPPLCHDYELR	
2285.0	28.1	1383-1402			1	AAQLPDMPLLEELGQVDCDR	
2315.1	-8.8	1021-1041			1	GRVCGLCGNFDDNAINDFATR	
2376.1	-28.0	1405-1424			2	GLMCANSQSQSPPLCHDYELR	
2878.1	22.1	328-351			4	TCPLNMQHQECGSPCTDCSNPQR	

* Sequence confirmed by MS/MS

B		Protein	SwissProt Accession	MW (Da)	pI	Unique Peptide Hits	% Coverage
		Mucin 5AC	Q8WWQ4	135520	9.11	10	14.68
m/z	Error (ppm)	Peptide Position			Alkylated Cysteines	Peptide Sequence	
862.4	-13.6	269-275, 567-573, 1000-1006			1	EEGLVCR	
900.5	37.0	238-244, 969-975				RPEEITR*	
1022.5	-12.6	223-230, 521-528, 954-961				ETYNIIIR	
1046.6	-87.7	178-187				TSTSHVSISK	
1061.5	-7.9	276-284, 574-582, 1007-1015				NQDQQGPFK*	
1084.5	-35.1	285-292, 583-590, 1016-1023			1	MCLNYEVR*	
1360.6	-30.1	495-504, 928-937			2	DCHPRCTWTK	
1848.0	-53.6	269-284, 567-582, 1000-1015				EEGLVCRNQDQQGPFK	
2062.1	-36.9	549-566			1	SHPEVSIIEHLGQVVQCSR	
2262.1	1.6	249-268, 980-999			1	AESHPVSIIEHLGQVVQCSR	

* Sequence confirmed by MS/MS

Table S2. Identification of gp-340 in submucosal gland secretions.

The high molecular weight glycoprotein in submucosal gland secretions migrating with a molecular mass of ~1 MDa by 1D SDS-AgPAGE was excised and digested with trypsin, and the resulting peptides were analysed by MALDI-TOF-MS. PMF searching identified the presence of gp-340 variant protein. Details of the protein identified, masses of the tryptic peptides detected, error to the theoretical peptide masses, the position of the peptides within each protein, and the peptide sequences are shown for non-CF lung disease subject 3. This data is representative of all subjects.

Protein	SwissProt Accession	MW (Da)	pI	Unique Peptide Hits	% Coverage			
Gp-340	Q9UKJ4	260591	5.18	11	19.9			
<i>m/z</i>	Error (ppm)	Peptide Position			Oxidised Methionine	Alkylated Cysteines	Peptide Sequence	
730.4	-1.7	104-110, 236-242, 365-371, 496-502, 604-610, 864-870, 995-1001, 1124-1130, 1253-1259, 1382-1388, 1511-1517, 1642-1648					LVNGDGR	
778.4	-38.2	247-252, 376-381, 507-512, 615-620, 746-751, 875-880, 1145-1140, 1264-1269, 1393-1398, 1653-1658					VEVLYR	
838.4	103.9	2360-2366					CKMVVCR	
991.6	-36.4	245-252, 1651-1658					GRVEVLYR	
1279.7	53.2	372-381, 503-512, 611-620, 742-751, 871-880, 1131-1140, 1260-1269, 1389-1398				1	CQGRVEVLYR	
1420.7	-82.3	2086-2098					GSFTSSSNFMSIR	
1459.8	-72.3	418-431, 549-562, 657-670, 788-801, 917-930, 1048-1061, 1177-1190, 1306-1319, 1435-1448, 1695-1708					FGQGS GPVLD D V R *	
1545.7	-82.0	403-417, 902-916, 1291-1305, 1420-1434				1	QLGCGWATSAPGNAR	
1575.7	-85.0	642-656, 773-787, 1162-1176, 1680-1694				1	QLGCGWAMSAPGNAR	
1591.7	-49.7	642-656, 773-787, 1162-1176, 1680-1694			1	1	QLGCGWAMSAPGNAR	
1601.8	-51.2	534-548				1	QLGCGWAMLAPGNAR	

* Sequence confirmed by MS/MS

Table S3. Monosaccharide compositions of *O*-linked oligosaccharides from MUC5B/MUC5AC. *O*-linked oligosaccharides were released by reductive β -elimination from MUC5B/MUC5AC in submucosal gland fluid. The resulting oligosaccharide alditols were analysed by LC-ESI-MS/MS, and their relative intensities were determined based on single-ion chromatograms. GlycoComp was used to determine the monosaccharide composition of the detected oligosaccharides. Masses corresponding to oligosaccharides, the monosaccharide composition of each oligosaccharide and the normalised percent abundance of each oligosaccharide from each subject are shown.

M	Composition	CF Lung Disease					Non-CF Lung Disease					Control		
		1	2	3	4	5	1	2	3	4	5	1	2	3
Neutral														
531.2	[1, 1, 1, 0, 0]					6.1					0.5			
588.1	[2, 1, 0, 0, 0]	0.8	0.9		1.4		1.7	1.9	0.8	1.0	3.9		16.2	
734.2	[2, 1, 1, 0, 0]	3.8	2.5	1.7		6.5		4.4	4.5	3.1		7.5		
750.3	[2, 2, 0, 0, 0]				1.9		3.2	1.0	1.7	1.2	1.4	0.8	2.9	
791.2	[3, 1, 0, 0, 0]							2.1	1.5	1.2			2.0	
880.2	[2, 1, 2, 0, 0]			0.7						0.3		1.6		
896.2	[2, 2, 1, 0, 0]		2.8	1.9		4.9		4.2	3.8	5.1		4.2	3.5	
937.2	[3, 1, 1, 0, 0]	6.3		6.4		6.2		4.8	3.0	1.1		12.7		
953.3	[3, 2, 0, 0, 0]						7.3	2.5	5.6	2.7	1.7	3.1	7.8	
1042.4	[2, 2, 2, 0, 0]			3.7		6.9		2.3	4.1	1.3		7.4		
1083.3	[3, 1, 2, 0, 0]	1.9		1.4				2.1	0.5					
1099.3	[3, 2, 1, 0, 0]	1.6	5.8	7.9		6.6	4.2	10.6	5.8	14.2	5.0	1.6	7.3	6.8
1140.4	[4, 1, 1, 0, 0]	6.4												
1188.3	[2, 2, 3, 0, 0]	1.5		2.3				2.3				3.1		
1204.4	[2, 3, 2, 0, 0]										2.3			
1245.4	[3, 2, 2, 0, 0]		8.1	16.8		16.8		14.7	13.1	6.1		21.9	2.8	
1261.3	[3, 3, 1, 0, 0]							0.7		2.6				
1286.5	[4, 1, 2, 0, 0]	4.6					1.5							
1350.5	[2, 3, 3, 0, 0]									2.4				
1391.3	[3, 2, 3, 0, 0]							8.7	3.8	1.7				
1407.3	[3, 3, 2, 0, 0]									1.7				
1448.4	[4, 2, 2, 0, 0]	7.0		8.0								7.6		
1594.4	[4, 2, 3, 0, 0]	8.5		1.2										
1798.0	[5, 2, 3, 0, 0]	1.7												
Sialylated														
676.2	[1, 1, 0, 1, 0]	3.6							0.7	1.0				
717.2	[2, 0, 0, 1, 0]	1.1		0.8					0.8	0.9				
879.1	[2, 1, 0, 1, 0]		1.9	1.1	1.2	1.7	2.0		1.8	1.4	1.4	2.2	0.9	3.5
967.2	[1, 1, 0, 2, 0]	1.5												
1025.2	[2, 1, 1, 1, 0]	1.1							1.1	0.9	2.0			
1041.5	[2, 2, 0, 1, 0]	3.2	7.6	1.4	4.7		4.9	1.6	3.0	2.7	3.4	4.6		
1082.3	[3, 1, 0, 1, 0]	6.7	9.4	6.8	1.9	4.0	2.9	3.0	1.6	2.9	3.8		5.4	
1187.4	[2, 2, 1, 1, 0]	2.4	9.6	5.3	9.9	8.7	7.3	1.4	12.5	6.4	6.4	6.3	2.2	16.5
1228.4	[3, 1, 1, 1, 0]						1.7		3.0					
1244.4	[3, 2, 0, 1, 0]	2.7	7.4	2.2		4.2	10.5	8.5	0.8	3.3	2.6	13.1		
1316.4	[2, 1, 1, 2, 0]								1.0					
1332.3	[2, 2, 0, 2, 0]	6.7			4.5	8.4	2.4		4.6	4.7				
1333.4	[2, 2, 2, 1, 0]		3.3	1.3		7.4				3.2				
1390.4	[3, 2, 1, 1, 0]	7.9	25.3	12.0	6.4	11.6	12.9	13.5	17.1	15.4	10.6	19.8	12.1	18.5
1478.4	[2, 2, 1, 2, 0]	3.7	5.8		12.2		5.0		3.4	1.4	4.9	3.9		
1535.4	[3, 2, 0, 2, 0]			2.5						1.4	1.9	5.3		
1536.7	[3, 2, 2, 1, 0]	0.6	7.2	7.3			1.7	4.5	3.9	3.5	3.1		6.1	
1552.3	[3, 3, 1, 1, 0]				4.1		2.3			3.7				
1593.5	[4, 2, 1, 1, 0]	9.8		2.2								10.0		
1681.3	[3, 2, 1, 2, 0]		2.6	1.7					9.0					
1698.0	[3, 3, 2, 1, 0]									0.4	1.8			
1698.8	[3, 3, 0, 2, 0]				1.7					1.2	0.8			
1739.4	[4, 2, 2, 1, 0]	3.3												
1756.0	[4, 3, 1, 1, 0]									0.6				
1828.0	[3, 2, 2, 2, 0]				1.7			2.4						
1844.0	[3, 3, 1, 2, 0]				3.0									
1901.0	[4, 3, 0, 2, 0]										1.5			
1902.2	[4, 3, 2, 1, 0]	0.9								1.7				
1990.4	[3, 3, 2, 2, 0]						2.2		1.6			4.1		
2064.2	[4, 4, 2, 1, 0]				2.1									
2192.8	[4, 3, 2, 2, 0]								1.4					
2208.6	[4, 4, 1, 2, 0]								0.5		0.9			
2209.8	[4, 4, 3, 1, 0]						2.1		1.2			1.5		
2280.8	[3, 3, 2, 3, 0]				4.2		1.6		2.6		1.5			
2282.9	[3, 3, 4, 2, 0]				2.5									
2354.8	[4, 4, 2, 2, 0]											3.0		
2499.6	[4, 4, 1, 3, 0]				4.1		2.1		1.5			3.8		
2500.8	[4, 4, 3, 2, 0]								1.8					
2646.4	[4, 4, 2, 3, 0]				5.9		4.2		3.7			5.3	4.3	
2791.2	[4, 4, 1, 4, 0]				4.1									
2792.4	[4, 4, 3, 3, 0]						2.0					2.7		
2866.6	[5, 5, 3, 2, 0]				3.6									
2994.6	[5, 4, 1, 4, 0]								1.6					
3156.4	[5, 5, 1, 4, 0]				3.1				3.5					
3157.0	[5, 5, 3, 3, 0]				3.7							4.8		
Sulfated														
959.1	[2, 1, 0, 1, 1]	2.1							1.3					
1105.3	[2, 1, 1, 1, 1]								1.4					
1121.2	[2, 2, 0, 1, 1]								5.1	1.3				
1179.2	[3, 2, 1, 0, 1]						2.2		1.3		1.0		4.5	
1267.1	[2, 2, 1, 1, 1]	0.5					1.9				0.7			
1470.2	[3, 2, 1, 1, 1]						2.0							
1471.6	[3, 2, 3, 0, 1]			1.7										
2014.0	[4, 5, 0, 1, 1]									1.0				
2143.6	[4, 4, 2, 1, 1]						2.0							
2433.8	[4, 4, 0, 3, 1]												5.2	
2580.6	[4, 4, 1, 3, 1]						2.3		1.5					
2799.9	[5, 5, 2, 2, 1]												5.4	
2945.4	[5, 5, 1, 3, 1]				6.2									
2946.2	[5, 5, 3, 2, 1]									2.0				
3311.0	[6, 6, 3, 2, 1]						2.9							

M, measured neutral reduced mass; Composition, [N -acetylhexosamine, hexose, fucose, N -acetylneuraminic acid, sulfate]. Assumption: All deoxyhexoses are fucose.

Table S4. Monosaccharide compositions of O-linked oligosaccharides from gp-340.

O-linked oligosaccharides were released by reductive β -elimination from gp-340 in submucosal gland secretions. The resulting oligosaccharide alditols were analysed by LC-ESI-MS/MS, and their relative intensities were determined based on single-ion chromatograms. GlycoComp was used to determine the monosaccharide composition of the detected oligosaccharides. Masses corresponding to oligosaccharides, the monosaccharide composition of each oligosaccharide and the normalised percent abundance of each oligosaccharide from each subject are shown. Although neutral oligosaccharides were only detected from subjects with non-CF lung disease, the low abundance of these components means that there are no significant differences in monosaccharide abundance between the subject groups.

M	Composition	CF Lung Disease					Non-CF Lung Disease					Control		
		1	2	3	4	5	1	2	3	4	5	1	2	3
Neutral														
588.1	[2 , 1 , 0 , 0 , 0]						1.9							
750.3	[2 , 2 , 0 , 0 , 0]						3.7							
896.2	[2 , 2 , 1 , 0 , 0]						1.0							
953.3	[3 , 2 , 0 , 0 , 0]						6.6							
1042.4	[2 , 2 , 2 , 0 , 0]									3.2				
1099.3	[3 , 2 , 1 , 0 , 0]						4.9			8.3				
1188.3	[2 , 2 , 3 , 0 , 0]										1.0			
1245.4	[3 , 2 , 2 , 0 , 0]									7.7				
1391.3	[3 , 2 , 3 , 0 , 0]									2.2				
2064.8	[4 , 4 , 4 , 0 , 0]										3.6			
Sialylated														
676.2	[1 , 1 , 0 , 1 , 0]	16.5	6.7											3.6
879.1	[2 , 1 , 0 , 1 , 0]						1.9							
967.3	[1 , 1 , 0 , 2 , 0]													6.0
1041.5	[2 , 2 , 0 , 1 , 0]						6.3			5.2				
1187.4	[2 , 2 , 1 , 1 , 0]				14.4		11.7			5.2	1.2			
1244.4	[3 , 2 , 0 , 1 , 0]						9.9							
1316.4	[2 , 1 , 1 , 2 , 0]	26.8	7.2	9.0	9.9									
1332.3	[2 , 2 , 0 , 2 , 0]	27.7	50.5	48.5	48.1	62.2	7.0	29.2	40.2	26.2	18.9	25.3	21.6	11.4
1390.4	[3 , 2 , 1 , 1 , 0]						22.6			7.1		3.9		
1478.4	[2 , 2 , 1 , 2 , 0]	16.7	15.0	18.5	42.3	37.8	11.9	14.8	14.7	10.5	20.0	15.1	16.8	25.1
1844.0	[3 , 3 , 1 , 2 , 0]										1.4			
1990.4	[3 , 3 , 2 , 2 , 0]										4.6	3.0		13.2
2208.8	[4 , 4 , 1 , 2 , 0]										1.6			
2353.6	[4 , 4 , 0 , 3 , 0]							8.3	8.5	6.4		10.1	20.0	
2280.8	[3 , 3 , 2 , 3 , 0]										4.2			
2499.6	[4 , 4 , 1 , 3 , 0]								17.2	19.1	9.0	14.8	30.0	8.1
2500.4	[4 , 4 , 3 , 2 , 0]	12.4	20.6	7.3			3.5	5.4			12.4			
2646.4	[4 , 4 , 2 , 3 , 0]							14.4	9.9	6.2	13.7	9.4	11.6	14.8
2791.2	[4 , 4 , 1 , 4 , 0]									7.7				
2792.4	[4 , 4 , 3 , 3 , 0]						6.1	10.8			13.6	7.6		13.9
Sulfated														
1105.3	[2 , 1 , 1 , 1 , 1]										2.9			
2579.8	[4 , 4 , 1 , 3 , 1]										3.9	5.0		

M, measured neutral reduced mass; Composition, [N -acetylhexosamine, hexose, fucose, N -acetylneuraminic acid, sulfate]. Assumption: All deoxyhexoses are fucose.

Table S5. Structures of *O*-linked oligosaccharides from MUC5B/MUC5AC. *O*-linked oligosaccharides were released by reductive β -elimination from MUC5B/MUC5AC in submucosal gland secretions. The resulting oligosaccharide alditols were analysed by LC-ESI-MS/MS, and their relative intensities were determined based on single-ion chromatograms. GlycosidIQ was used to assign structures to the detected oligosaccharides, which were also manually validated. Oligosaccharides were found to contain all major *O*-glycan cores, both chain types, and had terminal epitopes dominated by Lewis-type and blood group antigens. Masses corresponding to oligosaccharides, assigned oligosaccharide structures and the normalised percent abundance of each oligosaccharide from each subject are shown. Abbreviations: Fuc, fucose; Gal, galactose; GlcNAc, *N*-acetylglucosamine; GalNAc, *N*-acetylgalactosamine; NeuAc, *N*-acetylneuraminic acid; a – α linkage; b – β linkage; 1, 2, 3, 4, 6 – linked carbon position.

M	Structure	CF Diseased					non-CF Diseased					Control		
		1	2	3	4	5	1	2	3	4	5	1	2	3
Neutral														
531.2	Fuc(a1-2)Gal(b1-3)GalNAc					6.1								
588.2	Gal(b1-3)GlcNAc(b1-3)GalNAc											3.9		6.5
588.2	Gal(b1-4)GlcNAc(b1-3)GalNAc	1.0		1.4			1.3		1.7					
734.0	*Gal(b1-3)[GlcNAc(b1-6)]GalNAc													1.3
734.0	Fuc(a1-2)Gal(b1-3)[GlcNAc(b1-6)]GalNAc	1.1											1.5	
734.0	Fuc(a1-2)Gal(b1-3)GalNAc	1.0												
734.2	Fuc(a1-3/4)Gal(b1-3/4)GlcNAc(b1-3)GalNAc	0.4								3.9		3.9	3.1	
734.2	Fuc(a1-2)Gal(b1-3)GlcNAc(b1-3)GalNAc		2.5			4.8								4.8
734.2	Fuc(a1-2)Gal(b1-4)GlcNAc(b1-3)GalNAc					1.7								
750.3	Gal(b1-3)[Gal(b1-4)GlcNAc(b1-6)]GalNAc				1.9		2.9	1.0	1.5	1.2	1.7	0.8		2.5
750.3	Gal(b1-3)GlcNAc(b1-3)Gal(b1-3)GalNAc													2.2
791.2	GlcNAc(b1-3)[Gal(b1-3)GlcNAc(b1-6)]GalNAc								2.1					
791.2	GlcNAc(b1-3)[Gal(b1-4)GlcNAc(b1-6)]GalNAc									1.5	1.6			
880.3	Fuc(a1-2)Gal(b1-3/4)GlcNAc(b1-3/4)GlcNAc(b1-3)GalNAc													1.6
896.2	Fuc(a1-3/4)Gal(b1-3/4)GlcNAc(b1-3)Gal(b1-3)GalNAc													3.9
896.2	Gal(b1-3)[Fuc(a1-2)Gal(b1-4)GlcNAc(b1-6)]GalNAc		2.5	1.3		2.1		1.8		1.7	0.8			2.6
896.2	Fuc(a1-2)Gal(b1-3)[Gal(b1-3)GlcNAc(b1-6)]GalNAc					2.8				1.4				
896.2	Fuc(a1-2)Gal(b1-3)[Gal(b1-4)GlcNAc(b1-6)]GalNAc								1.6		1.1			
937.3	Fuc(a1-2)[GalNAc(a1-3)]Gal(b1-3/4)GlcNAc(b1-3)GalNAc													4.4
937.3	GlcNAc(b1-3)[Fuc(a1-2)Gal(b1-3)GlcNAc(b1-6)]GalNAc	6.3		1.4						3.0				
937.3	GlcNAc(b1-3)[Fuc(a1-2)Gal(b1-3)GlcNAc(b1-6)]GalNAc			6.0		6.2		4.1		2.7	1.2			8.3
953.3	Gal(b1-3/4)GlcNAc(b1-3)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc						7.3	2.4	5.6	2.7	2.2	3.1		8.6
1042.4	Fuc(a1-2)Gal(b1-3)[Fuc(a1-2)Gal(b1-4)GlcNAc(b1-6)]GalNAc			4.3		6.9		2.3		3.2	1.6			7.4
1083.0	Fuc(a1-2)[GalNAc(a1-3)]Gal(b1-3/4)GlcNAc(b1-3)GalNAc	2.2												
1083.0	GlcNAc(b1-3)[Fuc(a1-2)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc					1.6								
1099.3	Gal(b1-3)[Fuc(a1-2)GalNAc(a1-3)]Gal(b1-3/4)GlcNAc(b1-6)]GalNAc	2.1												
1099.3	Fuc(a1-3/4)Gal(b1-3/4)GlcNAc(b1-3)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc		2.4	3.2		2.4	4.2		5.2		1.2			
1099.3	Fuc(a1-2)Gal(b1-3)GlcNAc(b1-3)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc							8.2		4.2	2.9			4.7
1099.3	Gal(b1-3/4)GlcNAc(b1-3)[Fuc(a1-2)Gal(b1-4)GlcNAc(b1-6)]GalNAc		3.4	3.8		4.2		2.3		3.2				
1099.3	Gal(b1-3/4)GlcNAc(b1-3)[Fuc(a1-3/4)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc												1.6	7.5
1140.0	GlcNAc(b1-3)[Fuc(a1-2)GalNAc(a1-3)]Gal(b1-4)GlcNAc(b1-6)]GalNAc	6.6												
1188.3	Fuc(a1-2)Gal(b1-3)[Fuc(a1-2)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc			1.8			2.3							
1245.4	Fuc(a1-2)Gal(b1-4)GlcNAc(b1-3)GlcNAc(b1-3)Gal(b1-3)GalNAc		8.1	16.8		16.8		14.7		13.1	4.5			4.7
1245.4	Fuc(a1-2)Gal(b1-4)GlcNAc(b1-3)[Fuc(a1-2)Gal(b1-4)GlcNAc(b1-6)]GalNAc													13.0
1245.4	Fuc(a1-2)Gal(b1-3)[Fuc(a1-2)GalNAc(a1-3)]Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													4.2
1261.3	Fuc(a1-3/4)Gal(b1-3/4)GlcNAc(b1-3)Gal(b1-3)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc										1.1			
1286.0	GlcNAc(b1-3)[Fuc(a1-2)GalNAc(a1-3)]Gal(b1-3/4)GlcNAc(b1-6)]GalNAc	4.5							6.9		3.2			
1391.3	Fuc(a1-2)Gal(b1-3)GlcNAc(b1-3)[Fuc(a1-2)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													
1448.4	Fuc(a1-3/4)Gal(b1-3/4)GlcNAc(b1-3)[Fuc(a1-2)Gal(b1-4)GlcNAc(b1-6)]GalNAc				5.3									
1448.4	Fuc(a1-2)[GalNAc(a1-3)]Gal(b1-3)GlcNAc(b1-3)[Fuc(a1-2)Gal(b1-4)GlcNAc(b1-6)]GalNAc				4.0									
1448.4	Fuc(a1-2)[GalNAc(a1-3)]Gal(b1-3)GlcNAc(b1-3)[Fuc(a1-2)Gal(b1-3)GlcNAc(b1-6)]GalNAc													3.4
1448.4	Fuc(a1-2)Gal(b1-3)GlcNAc(b1-3)[Fuc(a1-2)GalNAc(a1-3)]Gal(b1-4)GlcNAc(b1-6)]GalNAc													4.2
Sialylated														
676.1	NeuAc(a2-3/6)Gal(b1-3)GalNAc	0.9												
676.1	Gal(b1-3)[NeuAc(a2-6)]GalNAc	2.5								0.8	1.1			
717.2	GlcNAc(b1-3)[NeuAc(a2-6)]GalNAc													
879.1	Gal(b1-3/4)GlcNAc(b1-3)[NeuAc(a2-6)]GalNAc												2.2	0.9
879.1	NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-3)GalNAc					1.2								
879.1	NeuAc(a2-3/6)Gal(b1-4)GlcNAc(b1-3)GalNAc	1.9				1.7								
879.1	NeuAc(a2-3/6)Gal(b1-3)[GlcNAc(b1-6)]GalNAc													0.9
967.0	NeuAc(a2-3/6)Gal(b1-3)[NeuAc(a2-6)]GalNAc	1.5												1.5
1025.2	Fuc(a1-2)Gal(b1-3)GlcNAc(b1-3)[NeuAc(a2-6)]GalNAc													
1025.2	Fuc(a1-3/4)Gal(b1-3/4)GlcNAc(b1-3)[NeuAc(a2-6)]GalNAc										1.2			
1041.5	Gal(b1-3)[NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc	1.0	7.6	1.6				1.6	3.0	2.2	4.2			
1041.5	Gal(b1-3)[NeuAc(a2-3/6)Gal(b1-4)GlcNAc(b1-6)]GalNAc							4.1						1.3
1041.5	NeuAc(a2-3/6)Gal(b1-3)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc	0.8			3.5									3.3
1082.3	GlcNAc(b1-3)[NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													
1082.3	NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-3)[GlcNAc(b1-6)]GalNAc													5.4
1187.4	NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-3)Gal(b1-3)GalNAc	2.2		7.8		5.0								
1187.4	NeuAc(a2-3/6)Gal(b1-3)[Fuc(a1-3/4)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc		1.5			4.3								4.6
1187.4	Gal(b1-3)[NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc		1.0			4.9		7.4	12.5		4.2			7.1
1187.4	Fuc(a1-2)Gal(b1-3)[NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc		7.1	3.2		4.4		1.4		5.1	3.9			1.7
1187.4	NeuAc(a2-3/6)Gal(b1-3)[Fuc(a1-2)Gal(b1-4)GlcNAc(b1-6)]GalNAc					2.9				1.1				2.2
1228.4	GlcNAc(b1-3)[NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc							1.7						
1228.4	NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-3/6)[GlcNAc(b1-6)]GalNAc									3.0				
1244.4	NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-3)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													
1244.4	NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-3/6)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													
1244.4	NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-3)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc	7.4				4.2		10.5		0.8	2.7	3.3	13.1	
1332.3	NeuAc(a2-3/6)Gal(b1-3)GalNAc	6.6				8.4					4.5			
1332.3	NeuAc(a2-3/6)Gal(b1-3)[NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc				5.9									4.2
1333.4	NeuAc(a2-3/6)Gal(b1-3)[Fuc(a1-2)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc					2.2								
1333.4	Fuc(a1-2)Gal(b1-3)[NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc		3.3			5.2								3.3
1390.4	Fuc(a1-3/4)Gal(b1-3/4)GlcNAc(b1-3)[NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc	21.9	10.6											10.3
1390.4	Fuc(a1-3/4)Gal(b1-3/4)GlcNAc(b1-3/6)[NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													
1390.4	Gal(b1-3/4)GlcNAc(b1-3)[NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													
1390.4	NeuAc(a2-3)Gal(b1-3/4)Fuc(a1-3/4)GlcNAc(b1-3)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc					11.6				13.8	3.1			19.8
1390.4	NeuAc(a2-3)Gal(b1-3/4)Fuc(a1-3/4)GlcNAc(b1-3/6)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													
1390.4	Fuc(a1-2)Gal(b1-3)GlcNAc(b1-3)[NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc		3.4		6.4									12.1
1390.4	Fuc(a1-2)Gal(b1-4)GlcNAc(b1-3)[NeuAc(a2-3/6)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc									13.5	1.2			
1478.4	NeuAc(a2-3)Gal(b1-3)[NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc		5.8	3.2										
1478.4	NeuAc(a2-3)Gal(b1-3)[NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc									3.4				
1536.7	Fuc(a1-3/4)Gal(b1-3/4)GlcNAc(b1-3)[NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc					12.1								
1536.7	Fuc(a1-2)Gal(b1-3/4)GlcNAc(b1-3)[NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc	5.1												
1536.7	Fuc(a1-2)Gal(b1-3/4)GlcNAc(b1-3)[NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													2.0
1536.7	Fuc(a1-2)Gal(b1-3/4)GlcNAc(b1-3)[NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc									4.5		2.6		
1536.7	NeuAc(a2-3)Gal(b1-3/4)Fuc(a1-3/4)GlcNAc(b1-3/6)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													3.9
1536.7	NeuAc(a2-3)Gal(b1-3/4)Fuc(a1-3/4)GlcNAc(b1-3/6)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													
1552.3	NeuAc(a2-3)Gal(b1-3/4)Fuc(a1-3/4)GlcNAc(b1-3/6)[Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													
1681.3	NeuAc(a2-3)Gal(b1-3/4)Fuc(a1-3/4)GlcNAc(b1-3/6)[NeuAc(a2-3)Gal(b1-3/4)GlcNAc(b1-6)]GalNAc													7.4
1681.3	NeuAc(a2-3)Gal(b1-3/4)Fuc(a1-3/4)GlcNAc(b1-3)[NeuAc(a2-3)Gal(b1-3/4)													